Is Semaglutide Legal in The EU? (2026 Research Status)

In the landmark STEP 1 trial, participants receiving semaglutide 2.4 mg once weekly experienced a mean body weight change of −14.9% over 68 weeks, compared with −2.4% in the placebo group Wilding et al., 2021. That single statistic captures why semaglutide has become one of the most discussed — and most regulated — molecules of the decade.

But what does the European regulatory picture actually look like? If you’re a researcher, clinician, or someone simply trying to understand the rules, the answer is layered. This guide walks through the history, the current framework, and the nuances that matter in 2026.

What Is Semaglutide? A Brief Primer

Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose metabolism and appetite signaling. The molecule was engineered to resist rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), giving it a significantly longer half-life than native GLP-1 — approximately one week when administered subcutaneously Knudsen & Lau, 2019.

This extended half-life is what makes once-weekly dosing feasible, a practical advantage that helped propel semaglutide through clinical development and into global regulatory discussions.

At its core, semaglutide works by activating GLP-1 receptors, which research suggests may influence insulin secretion in a glucose-dependent manner, slow gastric emptying, and modulate central appetite pathways. These mechanisms have been explored across two broad clinical domains: glycemic management in type 2 diabetes and body weight research in higher-dose formulations.

From Lab to Approval: The Regulatory Journey

Understanding semaglutide’s legal status in the EU requires following the chronological arc of its development.

2012–2016: Discovery and Early Trials

Semaglutide was developed by Novo Nordisk as a successor to liraglutide, their earlier GLP-1 receptor agonist. The early clinical program focused on glycemic outcomes, with the SUSTAIN trial series evaluating semaglutide in populations with type 2 diabetes. The SUSTAIN-6 cardiovascular outcomes trial was a pivotal moment: it suggested that semaglutide was associated with a 26% reduction in major adverse cardiovascular events (MACE) compared to placebo over a median follow-up of two years Marso et al., 2016.

2018: EMA Authorizes Ozempic

In February 2018, the European Medicines Agency (EMA) granted marketing authorization for Ozempic (semaglutide 0.5 mg and 1.0 mg once-weekly injection) for the treatment of type 2 diabetes in adults. This authorization made semaglutide a legally marketed prescription medicine across all EU member states, subject to national pricing and reimbursement processes.

2021–2022: The STEP Trials and a New Indication

The STEP (Semaglutide Treatment Effect in People with obesity) program shifted attention toward higher-dose semaglutide. STEP 1 demonstrated the −14.9% weight change cited above, and subsequent trials reinforced this signal. STEP 5, for instance, indicated that sustained weight loss could be maintained over two years with continued treatment Rubino et al., 2021.

In January 2022, the EMA authorized Wegovy (semaglutide 2.4 mg once weekly) for weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. This was a significant regulatory milestone: it placed a GLP-1 receptor agonist explicitly within the EU’s weight management framework for the first time.

The Current Legal Landscape (2026)

Here’s where things get nuanced. The question “Is semaglutide legal in the EU?” doesn’t have a single answer — it depends on the specific product, its source, and its intended use.

Authorized Products

Both Ozempic and Wegovy remain EMA-authorized and are legal prescription medicines throughout the EU. A licensed physician can prescribe them, and a licensed pharmacy can dispense them. This is the straightforward part.

Compounded Semaglutide

The situation with compounded semaglutide is considerably more complex and varies by member state. Compounding pharmacies in the EU operate under different frameworks than in the United States. In general, EU regulations around compounding are more restrictive: pharmacies may prepare individualized preparations for specific patients based on a physician’s prescription, but bulk compounding for distribution is typically not permitted under the same exemptions.

Some member states have tightened their positions since 2023 amid global supply shortages and rising demand. The regulatory concern centers on quality assurance — compounded preparations may not undergo the same rigorous quality controls as centrally authorized products. If you’re navigating this space, our guide on where to buy semaglutide in 2026 covers sourcing considerations in more detail.

Research-Grade Semaglutide

A separate category exists for research chemicals and peptide suppliers selling semaglutide labeled “for research purposes only.” Under EU law, compounds sold strictly for in vitro research or laboratory use are not classified as medicinal products and therefore fall outside EMA jurisdiction. However, this classification is only legitimate if the compound is genuinely used for research and not for human consumption.

This distinction matters enormously. The moment a research-grade substance is intended for self-administration, it functionally becomes an unauthorized medicinal product — and selling or distributing it as such would likely violate EU Directive 2001/83/EC (the Community code relating to medicinal products for human use).

For a broader discussion of how peptide legality has evolved, see our recent post on peptide legality in 2026.

Supply Shortages and Parallel Imports

One factor that has complicated the EU picture since 2022 is supply. Semaglutide products have experienced intermittent shortages across multiple member states, driven by unprecedented global demand. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has acknowledged these shortages, and national competent authorities have issued varying guidance.

Some countries have restricted prescribing of semaglutide for weight management to preserve supply for diabetes patients. Others have permitted parallel imports — the cross-border movement of authorized products between EU member states — as a short-term mitigation strategy. These parallel imports are legal under EU single-market rules but add another layer of complexity to the sourcing question.

Regulatory Trends to Watch

Several developments may shape the semaglutide regulatory landscape in the EU going forward:

• Biosimilar and generic competition: Semaglutide’s core patent is expected to face challenges in the coming years. Generic entry could reshape access and pricing.
• Updated EMA guidance on GLP-1 receptor agonists: As new data emerge from ongoing cardiovascular and metabolic trials, label expansions or new safety communications are possible.
• National-level restrictions: Individual member states retain significant discretion in prescribing guidelines, reimbursement criteria, and supply management. The EU framework sets the floor, but national policies set the practical reality.
• Online pharmacy regulation: The growth of online pharmacies selling semaglutide (or compounds claiming to be semaglutide) has prompted increased enforcement attention from national regulators.

What the Research Context Suggests

It’s worth emphasizing that semaglutide’s EMA authorizations are based on clinical trial programs involving tens of thousands of participants. The evidence base is substantial, and it continues to grow. Research suggests that semaglutide may influence body weight and glycemic markers through mechanisms that are increasingly well-characterized at the receptor level Knudsen & Lau, 2019.

That said, authorized use and research context are different things. Clinical trials operate under controlled conditions with rigorous monitoring. The translation of those findings into real-world outcomes is an ongoing area of study, and the long-term profile of semaglutide in broader populations is still being characterized.

For a complete overview of the compound itself, including its chemistry, pharmacokinetics, and the full body of research, visit our semaglutide compound page.

Frequently Asked Questions

Is semaglutide a controlled substance in the EU?

No. Semaglutide is not classified as a controlled substance under EU narcotics or psychotropic substance legislation. It is a prescription-only medicinal product when sold in its authorized forms (Ozempic, Wegovy). The distinction between a prescription medicine and a controlled substance is important — they carry different legal frameworks and different penalties for misuse.

Can I legally buy semaglutide online in the EU?

You can legally obtain semaglutide through licensed online pharmacies that operate within EU regulations, provided you have a valid prescription from a licensed EU physician. Buying from unregulated sources — particularly those selling “research-grade” peptides intended for self-administration — carries both health risks and potential legal exposure, depending on your jurisdiction.

Why is semaglutide sometimes hard to find in EU pharmacies?

Since 2022, global demand for semaglutide has outpaced supply. Novo Nordisk has expanded manufacturing capacity, but shortages have persisted in several member states. Some national health authorities have issued prescribing restrictions to prioritize patients with type 2 diabetes, which further limits availability for weight management use.

Is compounded semaglutide legal in my country?

This depends entirely on national law. Some EU member states permit extemporaneous compounding by licensed pharmacists based on an individual prescription. Others have imposed additional restrictions since 2023. There is no uniform EU-wide answer, and the regulatory picture continues to evolve. Consulting your national pharmacy regulatory authority is the most reliable approach.

What’s the difference between authorized and research-grade semaglutide?

Authorized semaglutide (Ozempic, Wegovy) has undergone full EMA evaluation for quality, safety, and efficacy. Research-grade semaglutide is sold for laboratory use and has not been evaluated by any regulatory authority for human use. The purity, sterility, and potency of research-grade products may vary significantly from authorized formulations.